RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

Conference taking place on March 27-29, 2025 in New Orleans -- -- CAGLA NeauxCancer Conference is a leading global forum in ...

After months of waiting, a young boy from Cuba battling a medical condition is getting a second chance at life after he and ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

In nearly three years of full-scale war, Ukrainian families of children with long-term illnesses have had to overcome ...

Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

We are grateful for the support from the Children’s Tumor Foundation, a vital partner in this journey, and to the Neurofibromatosis Clinical Trials Consortium for making this clinical trial a ...

Once again, the unsanctioned Ginger Run at the University of Delaware drew hundreds of redheads, even more spectators and a ...

HALIFAX – Nova Scotia still hasn’t signed on to the federal government’s pharmacare plan, and the province’s Opposition New ...

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.